Skip to main content
SpringerLink
Log in

Availability of triptans over-the-counter (OTC) for the treatment of migraine has advantages and disadvantages

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs 2007; 21(11): 877–83

    Article  PubMed  CAS  Google Scholar 

  2. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, et al., editors. The headaches. 3rd ed. Philadelphia (PA): Lippincott, Williams & Wilkins, 2006: 469–503

    Google Scholar 

  3. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine: a meta-analysis of 53 trials. Lancet 2001 Nov 17; 358(9294): 1668–75

    Article  PubMed  CAS  Google Scholar 

  4. Ferrari MD. Should we advise patients to treat migraine attacks early? Cephalalgia 2004 Nov; 24(11): 915–7

    Article  PubMed  CAS  Google Scholar 

  5. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Triptan Cardiovascular Safety Expert Panel. Headache 2004 May; 44(5): 414–25

    Article  PubMed  Google Scholar 

  6. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004 Nov; 24(11): 947–54

    Article  PubMed  CAS  Google Scholar 

  7. Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10mg vs naratriptan 2.5mg in migraine. Eur Neurol 1999; 42(3): 173–9

    Article  PubMed  CAS  Google Scholar 

  8. Garcia-Ramos G, MacGregor EA, Hilliard B, et al. Comparative efficacy of eletriptan vs naratriptan in the acute treatment of migraine. Cephalalgia 2003 Nov; 23(9): 869–76

    Article  PubMed  CAS  Google Scholar 

  9. Dowson AJ, Dodick DW, Limmroth V. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs 2005; 19(6): 483–97

    Article  PubMed  Google Scholar 

  10. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 2006 Jun 27; 66(12): 1894–8

    Article  PubMed  Google Scholar 

  11. Andlin-Sobocki P, Jönsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005 Jun; 12Suppl. 1: 1–27

    Article  PubMed  Google Scholar 

  12. Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007 Apr; 49(4): 368–74

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Availability of triptans over-the-counter (OTC) for the treatment of migraine has advantages and disadvantages. Drugs Ther. Perspect 24, 22–23 (2008). https://doi.org/10.2165/00042310-200824080-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824080-00007

Search

Navigation